Long‐term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non‐Hodgkin lymphomaPeter Martin, John P. Leonard, Jonathan W. Friedberg et al.|British Journal of Haematology|2017Cited by 33
Bendamustine HCl (TREANDATM) Treatment in Combination with Rituximab Results in Objective Responses in Patients with Refractory/Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin’s Lymphoma: Results from Phase II Multicenter Study (SDX-105-02).Katherine Robinson, Ely Benaim, Michael E. Williams et al.|Blood|2005Cited by 9
Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin LymphomaPeter Martin, John P. Leonard, Zhengming Chen et al.|Blood|2015Cited by 0